Evidence map›Paper›PMID 30984181›Full record

ArticleFrontiers in immunology2019

Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc

Felix Wagner, Ulrike Hölig, Friederike Wilczkowski, Ioana Plesca, Ulrich Sommer, Rebekka Wehner, Maximilian Kießler, Armin Jarosch, Katharina Flecke, Maia Arsova and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Tertiary lymphoid structures in colorectal cancer - organization and immune cell interactions.American journal of clinical and experimental immunology · 2024
    Review
  3. Review
  4. Observational
  5. Review
  6. CD11cOncoimmunology · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Felix WagnerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Ulrike HöligInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Friederike WilczkowskiInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Ioana PlescaInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Ulrich SommerInstitute of Pathology, University Hospital of Dresden, Dresden, Germany.
Rebekka WehnerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Maximilian KießlerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Armin JaroschInstitute of Pathology, University Hospital of Dresden, Dresden, Germany.
Katharina FleckeInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Maia ArsovaInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Antje TungerInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Andreas BognerDepartment of Gastrointestinal, Thoracic, and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Christoph ReißfelderDepartment of Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany.
Jürgen WeitzPartner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany.
Knut SchäkelDepartment of Dermatology, University Hospital of Heidelberg, Heidelberg, Germany.
Esther G C TroostDepartment of Radiotherapy and Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Mechthild KrauseDepartment of Radiotherapy and Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Gunnar FolprechtPartner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany.
Martin BornhäuserPartner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany.
Michael P BachmannPartner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany.
Daniela AustInstitute of Pathology, University Hospital of Dresden, Dresden, Germany.
Gustavo BarettonInstitute of Pathology, University Hospital of Dresden, Dresden, Germany.
Marc SchmitzInstitute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
University Hospital Carl Gustav Carus · DETU Dresden · DEHeidelberg University · DENational Center for Tumor Diseases · DEGerman Cancer Research Center · DEHelmholtz-Zentrum Dresden-Rossendorf · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant radiochemotherapy (nRCT) can significantly influence the tumor immune architecture that plays a pivotal role in regulating tumor growth. Whereas, various studies have investigated the effect of nRCT on tumor-infiltrating T cells, little is known about its impact on the frequency and activation status of human dendritic cells (DCs). Plasmacytoid DCs (pDCs) essentially contribute to the regulation of innate and adaptive immunity and may profoundly influence tumor progression. Recent studies have revealed that higher pDC numbers are associated with poor prognosis in cancer patients. 6-sulfo LacNAc-expressing monocytes (slanMo) represent a particular proinflammatory subset of human non-classical blood monocytes that can differentiate into DCs. Recently, we have reported that activated slanMo produce various proinflammatory cytokines and efficiently stimulate natural killer cells and T lymphocytes. slanMo were also shown to accumulate in clear cell renal cell carcinoma (ccRCC) and in metastatic lymph nodes from cancer patients. Here, we investigated the influence of nRCT on the frequency of rectal cancer-infiltrating pDCs and slanMo. When evaluating rectal cancer tissues obtained from patients after nRCT, a significantly higher density of pDCs in comparison to pre-nRCT tissue samples was found. In contrast, the density of slanMo was not significantly altered by nRCT. Further studies revealed that nRCT significantly enhances the proportion of rectal cancer-infiltrating CD8

Indexed as

ChemoradiotherapyNeoadjuvant TherapyRectal NeoplasmsAdultAgedAmino SugarsCarcinoma, Renal CellDendritic CellsFemaleHumansKidney NeoplasmsMaleMiddle AgedMonocytesNeoplasm MetastasisRetrospective Studies6-sulfo-LacNacAmino Sugars6-sulfo LacNAc+ monocytesCD8+ T cellsplasmacytoid dendritic cellsradiochemotherapyrectal cancertumor immune architecture

Identifiers

PMID30984181
PMCPMC6450462
OpenAlexW2927126716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.